Treatment of Relapse and Refractory Hodgkin Lymphoma

Oncogematologiya - Russian Federation
doi 10.17650/1818-8346-2017-12-2-8-13
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Publishing House ABV Press

Related search

Treatment of Relapsed and Refractory Hodgkin Lymphoma – Recommendations of the Czech Hodgkin Lymphoma Study Group

Klinicka Onkologie
Oncology
2016English

Profile of Brentuximab Vedotin and Its Potential in the Treatment of Relapsed or Refractory Hodgkin Lymphoma

Blood and Lymphatic Cancer: Targets and Therapy
2012English

Molecular Landscape of Relapse/Refractory Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Treating Hodgkin Lymphoma in the New Millennium: Relapsed and Refractory Disease

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

The Role of Cytotoxic and Regulatory T Cells in Relapsed/Refractory Hodgkin Lymphoma

Applied Immunohistochemistry and Molecular Morphology
Forensic MedicinePathologyMedical Laboratory TechnologyHistology
2010English

Rapidly Progressing Refractory Hodgkin Lymphoma: A Case Report and a Possible Explanation

Case Reports in Medicine
Medicine
2016English

On the Prediction of Hodgkin Lymphoma Treatment Response

Clinical and Translational Oncology
MedicineCancer ResearchOncology
2015English

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Annals of Hematology
MedicineHematology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy